July 30, 2021
Sumitomo Dainippon Pharma’s group revenue in April-June slipped 2.0% versus a year ago as sales of its antipsychotic Latuda (lurasidone) in North America declined in a pullback from the previous quarter, which saw a spike in the drug’s shipments. In...read more